Amarin has entered 2026 from an improved position of market, operational, and financial strength, maintaining U.S. leading market share for VASCEPA and actively expanding presence in Europe for VAZKEPA. The company expects to generate positive cash flow for the full year in 2026 through cost-efficient revenue generation with its U.S. franchise and new international business model while operating with a significantly improved OpEx profile.
Cyborg Score Rationale
Amarin improved its cash position to $303 million with no debt and achieved positive cash flow in Q4 2025 ahead of schedule. The company realized $31 million of expected $70 million in cost savings from restructuring initiatives. Strong market position in U.S. with strategic international partnerships positions the company for sustainable growth.
Top Insights
Q4 2025 operating loss narrowed to $6.3 million from $52.5 million in Q4 2024, a 88% improvement.
The company secured regulatory approvals in South Korea and Singapore in 2025 and is advancing reviews in Thailand and Philippines with new filings expected in Vietnam and Malaysia.
Recordati partnership has strengthened Amarin's presence in Europe and defined its fully partnered international commercial strategy.
Return to positive cash flow achieved ahead of schedule positions the company to generate positive cash flow for 2026.
Named Competitors
Crestor/Rosuvastatin — Statin therapy for CVD risk reduction
Repatha/Evolocumab — PCSK9 inhibitor for high cholesterol
Inclisiran — LDL cholesterol reduction therapy
Recent Developments
(February 2026) Amarin reported Q4 and full-year 2025 financial results showing 88% operating loss improvement and $303M cash position with no debt
(2025) Secured regulatory approvals in South Korea and Singapore; expanded Italian commercialization and secured pricing in Austria and Slovenia
(2025) Completed $70M annualized cost savings restructuring with $36.2M in charges incurred
Open the full interactive Amarin Corporation plc report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.